Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, October 21, 2016

Cancer researcher retracts 19 ovarian cancer studies at once - Retraction Watch

Cancer researcher retracts 19 studies at once - Retraction Watch
 October 21st, 2016
Tracking retractions as a window into the scientific process

A former cancer biologist at the Moffitt Cancer Center in Tampa, Florida has retracted 19 papers from a single journal.

Jin Cheng, who studies how ovarian cancer develops, withdrew 19 papers from the Journal of Biological Chemistry originally published over the last 15 years, and corrected another. All of the retractions are for image manipulation.

For example, here’s the notice for “Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src,” a paper originally published in 2003:
This article has been withdrawn by the authors. The same data were used to represent different experimental conditions. Specifically, lanes 1–3 of the H2B panel of Fig. 4Bwere reused in lanes 1–3 of the H2B panel from Fig. 6B. Lanes 1 and 6 of the phospho-Akt panel from Fig. 4C were duplicated. Lanes 3 and 4 of the lower FLAG panel in Fig. 4Cwere reused in lanes 7 and 8 of the lower FLAG panel in Fig. 5A. The PI(3,4)P2 spots from lanes 1 and 2 from Fig. 7 were reused in lanes 7 and 8 of the same panel. Additionally, some PI(4)P1 spots were pasted in. The authors state that the overall conclusions of this work are not affected.
Cheng has been awarded multiple NIH R01 grants, totaling millions of dollars, according to NIH RePORTER. A person answering the phone number listed for Cheng’s lab said he had retired. The email address listed on many of his papers bounced.
Here are the 19 retractions:
The current issue of the JBC also includes a correction of one of Cheng’s papers, “Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β. LncRNA-HIT-MEDIATED TGF-INDUCED EPITHELIAL TO MESENCHYMAL TRANSITION IN MAMMARY EPITHELIA,” a study that has been cited 17 times.

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset (clear cell) epithelial ovarian cancer

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer | Hereditary Cancer in Clinical Practice | Full Text


Cancer genetic counseling should be always offered during the work-up of young patients with epithelial ovarian cancer, in order to screen the presence of a hereditary syndrome and to improve the oncological follow-up including intensified surveillance. Clinicians should be particularly careful to the evaluation of a positive family history of cancer, being ovarian cancer involved in three different syndromes, such as site-specific, HBOC and Lynch Syndrome.

Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy

abstract (Korea)


We explored patients' preferences for adding bevacizumab to first-line therapy.
A discrete choice experiment and trade-off question were designed and distributed to ovarian cancer patients.
Patients' preferences for bevacizumab depend primarily on drug costs.


The GOG-218 and ICON-7 studies recently showed that adding bevacizumab to first-line therapy for patients with advanced ovarian cancer increased progression-free survival. However, the high cost and long treatment duration prevents the incorporation of bevacizumab in practice. The aim of this study was to explore and quantify patients' preferences for adding bevacizumab to first-line therapy.

Gynecologic Oncology journal Index: November 2016 (not open access)

November 2016

Thursday, October 20, 2016

Adhesive Small Bowel Obstruction Managed by a Surgical Team (NY)



This study demonstrates that primary management of patients with adhesive-SBO by medical services is associated with longer LOS, larger cost, and higher readmission rates, as well as a delay in time to surgery and higher mortality rates following surgical intervention. While complex patients with multiple comorbidities may benefit from medical optimization by hospitalists, institutional policies favoring primary management by surgical services may greatly reduce healthcare utilization and improve outcomes for patients admitted with adhesive-SBO.

Trauma Patients Not to Blame for Opioid Epidemic: Study

med news

WEDNESDAY, Oct. 19, 2016 -- Patients who survived major trauma may not be a significant factor in the U.S. opioid epidemic, a new study suggests.
Almost 75 percent of major trauma patients who were prescribed narcotic painkillers such as OxyContin and Percocet had stopped using them a month after leaving the hospital. And only 1 percent were still taking the drugs on a prescription basis a year later, researchers found....

Many officials attribute some of this abuse to overprescribing practices, arguing that use of legitimate pain pills frequently leads to addiction.
However, "our findings in patients who sustain traumatic injury contradict the popular narrative about the role that appropriate use of opioids may play in the rate of opioid abuse in this country," Schoenfeld said.
 The report was scheduled for presentation Wednesday at the annual meeting of the American College of Surgeons in Washington, D.C. Data and conclusions presented at meetings are generally considered preliminary until published in a peer-reviewed medical journal.

Wednesday, October 19, 2016

Ovarian Cancer Trial Stopped Due to Low Response (Zytiga (abiraterone)


Streamlined BRCA Testing Program Shows Promise in Ovarian Cancer


Controversy Remains on Addition of VEGF Inhibition Before Interval Debulking in Ovarian Cancer


Perspective: A Precision Medicine Approach to Clinical Trials (note reference to patients/Facebook)

Cancer Biomarkers | JAMA

 “They say, ‘Dr Hong, I want to be in this trial,’” said Hong, deputy chair of the department of investigational cancer therapeutics at the University of Texas MD Anderson Cancer Center. “Patients are incredibly savvy. Especially if they have end-stage cancer and their doctor has told them, ‘there’s nothing more I can do for you,’ they will find a trial.”

In postmenopausal women, oral but not transdermal estrogen was associated with increased risk for stroke

In postmenopausal women, oral but not transdermal estrogen was associated with increased risk for stroke (paywalled)

Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees


Background: Drug advisory committees provide independent advice to the U.S. Food and Drug Administration (FDA) on policy matters. Committee members are special government employees and are subject to federal employee conflict-of-interest guidelines under 18 U.S.C. § 208 and § 712 (1994). Although these regulations prohibit actual or apparent conflicts of interest, regulatory policy allows waivers to be issued when the participant's expertise is deemed essential to evaluating a specific matter before the advisory committee. The issuance of waivers can be complicated, but the FDA is clear that relevant scientific expertise is a necessary and primary criterion (1). Therefore, patient and consumer representatives are ineligible to receive waivers for conflicts of interest (1). In addition, committee members with more than $50 000 in financial relationships are typically ineligible for waivers regardless of expertise.

CRU: Straight from a Nutrition Conference, What Dietitians Get Asked the Most


Injuries before and after diagnosis of cancer: nationwide register based study + comment/s

i·at·ro·gen·ic īˌatrəˈjenik/ adjective adjective: iatrogenic
  1. of or relating to illness caused by medical examination or treatment.
 We used the Swedish revision of ICD-7 (international classification of diseases, seventh revision) to classify cancers as prostate cancer (n=123 837), breast cancer (n=101 458; women only), colorectal cancer (n=84 527), non-melanoma skin cancer (n=33 409), lymphatic or hematopoietic cancers (n=52 266), lung cancer (n=49 491), cancers of the central nervous system (n=21 199), cancers with an expectedly short survival
(n=34 627; “severe cancers” including cancers in the oesophagus, liver, and pancreas), and other cancers (n=220 087).
open access

 Based on this register, we included 740 114 unique patients with a first cancer diagnosed during 1991-2009.